Treace Medical CEO reports 19.2% ownership stake
Treace Medical Concepts, Inc. reported that its Chief Executive Officer, John T. Treace, filed an amended Schedule 13G reflecting his ownership in the company’s common stock as of June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Treace Medical Concepts, Inc. reported that its Chief Executive Officer, John T. Treace, filed an amended Schedule 13G reflecting his ownership in the company’s common stock as of June 30, 2026. Based on 64,976,624 shares of common stock outstanding, he may be deemed the beneficial owner of 12,530,959 shares, representing 19.2% of the class.
The position includes shares held directly by John T. Treace, multiple family trusts for which he or his spouse serve as trustee or co-trustee, his spouse’s holdings, and 401,175 shares underlying stock options that are currently exercisable or will be exercisable within 60 days of June 30, 2026. He has 9,045,893 shares with sole voting and dispositive power and 3,485,066 shares with shared voting and dispositive power.
Key Figures
Key Terms
beneficial owner financial
sole voting power financial
stock options financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Treace Medical Concepts (TMCI) does John T. Treace own?
What portion of John T. Treace’s TMCI holdings are stock options?
How are family trusts and spouse holdings treated in John T. Treace’s TMCI ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.